ClinicalTrials.gg
Status unknownNCT02001285Updated Dec 4, 2013

Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Double-lumen Endobronchial Intubation

An interventional study of Remifentanil in Intubation, Intratracheal, sponsored by Jeju National University School of Medicine. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-12-04.

Sponsored by Jeju National University School of Medicine · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Nov 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is the comparison of the effect-site concentration of remifentanil for blunting hemodynamic responses to ordinary tracheal and double-lumen endobronchial intubation during propofol-remifentanil total intravenous anesthesia.

02

Conditions studied

  • Intubation, Intratracheal

Keywords

  • remifentanil
03

In context

Lead sponsor

Jeju National University School of Medicine is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient who is needed intubation for general anesthesia

Exclusion criteria

Exclusion Criteria:

  • patient who is anticipating difficult airway
  • patient who takes any drug to influence this study
  • cardiovascular disease, renal disease, liver disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Double lumen tube

    This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.

    Drug: Remifentanil

  • Active comparator
    single lumen tube

    This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.

    Drug: Remifentanil

Interventions

  • During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.

    Also known as: Ultiva (TM)

06

What researchers measure

Primary outcomes

  1. arterial blood pressure

    Arterial blood pressure will be recorded before anesthesia, after propofol infusion, after remifentanil infusion and after intubation during 3 min with 1 min interval.

    Time frame: Change from baseline in arterial blood pressure at intubation period

Secondary outcomes

  1. heart rate

    Heart rate will be recorded before anesthesia, after propofol infusion, after remifentanil infusion and after intubation during 3 min with 1 min interval.

    Time frame: Change from baseline in heart rate at intubation period

07

Study locations

1 of 1 sites recruiting
  • Jeju National University Hospital
    Jeju-si, Jeju Special Self-Governing Province 690-767, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2013
First posted
Dec 4, 2013
Start
Oct 2013
Primary completionEst.
Sep 2015
CompletionEst.
Sep 2015
Last update
Dec 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02001285
Lead sponsor
Jeju National University School of Medicine
Responsible party
Hyun Jung Kim (Assistant professor, Jeju National University School of Medicine) — Principal investigator
First posted
Dec 4, 2013
Start date
Oct 2013
Primary completion
Sep 2015 (estimated)
Completion
Sep 2015 (estimated)
Last update
Dec 4, 2013

Study contacts

Hyun Jung Kim, MD, PhD
Contact
hjanesthesia@empas.com
82-64-717-2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remifentanil

Start the discussion